Published in Mol Ther Methods Clin Dev on December 18, 2016
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
Transcription start regions in the human genome are favored targets for MLV integration. Science (2003) 12.21
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res (2014) 10.77
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 8.27
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet (2006) 6.43
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
The UCSC Genome Browser database: 2015 update. Nucleic Acids Res (2014) 4.87
Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med (2010) 3.09
Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity (1998) 2.92
Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med (1999) 2.81
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
WASP: a key immunological multitasker. Nat Rev Immunol (2010) 2.38
The Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2006) 2.29
Chromatin boundaries and chromatin domains. Cold Spring Harb Symp Quant Biol (2004) 2.08
Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther (2002) 2.03
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood (2004) 1.99
Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA (2015) 1.97
WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med (2011) 1.91
Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol (1995) 1.90
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood (2009) 1.89
Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest (2007) 1.77
Insulators and promoters: closer than we think. Nat Rev Genet (2010) 1.66
Wiskott-Aldrich syndrome. Curr Opin Hematol (2008) 1.59
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood (2007) 1.57
Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood (2004) 1.56
Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther (2009) 1.43
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia (2008) 1.35
Hematopoietic stem-cell behavior in nonhuman primates. Blood (2007) 1.27
B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood (2012) 1.27
Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol (2014) 1.24
Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther (2009) 1.15
Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther (2014) 1.13
The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther (2011) 1.11
Gene therapy for severe combined immunodeficiency. Annu Rev Med (2005) 1.11
Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. J Virol (2005) 1.10
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
VISA--Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing. BMC Bioinformatics (2015) 1.07
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood (2010) 1.06
A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood (2003) 1.04
Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders. Mol Ther (2010) 1.04
Large animal models of hematopoietic stem cell gene therapy. Gene Ther (2010) 1.03
High-throughput genomic mapping of vector integration sites in gene therapy studies. Methods Mol Biol (2014) 1.02
Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood (2012) 0.99
Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin Allergy Clin Immunol (2011) 0.93
Structure and function of the Wiskott-Aldrich syndrome protein. Curr Opin Hematol (2005) 0.92
Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells. J Immunol (2009) 0.91
Charting a clear path: the ASGCT Standardized Pathways Conference. Mol Ther (2014) 0.89
A 5' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. Blood (1998) 0.89
Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin Invest (2015) 0.88
Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors. Hum Gene Ther Clin Dev (2013) 0.87
B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2015) 0.86
Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector. PLoS One (2013) 0.85
Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy. Mol Ther Methods Clin Dev (2015) 0.84
[Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector]. Bull Acad Natl Med (2010) 0.84
Stem cell gene therapy, position effects and chromatin insulators. Stem Cells (1997) 0.84
Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies. Mol Ther Methods Clin Dev (2014) 0.81
B-cell intrinsic TLR7 signals promote depletion of the marginal zone in a murine model of Wiskott-Aldrich syndrome. Eur J Immunol (2015) 0.80
Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes. Mol Ther (2016) 0.76
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med (2015) 1.30
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. Mol Ther (2017) 0.81